GenSight Biologics S.A.
GSGTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | -$0 | $2 | -$0 |
| % Growth | 121.1% | -113.2% | 710.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $3 |
| Gross Profit | $0 | -$0 | $2 | -$2 |
| % Margin | 100% | 100% | 100% | 849.5% |
| R&D Expenses | $5 | $6 | $6 | $7 |
| G&A Expenses | $2 | $1 | $3 | $2 |
| SG&A Expenses | $3 | $1 | $3 | $5 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $3 |
| Other Operating Expenses | -$1 | $1 | $0 | $0 |
| Operating Expenses | $7 | $8 | $9 | $13 |
| Operating Income | -$8 | -$8 | -$7 | -$13 |
| % Margin | -17,318.9% | 3,688.6% | -428.4% | 4,453% |
| Other Income/Exp. Net | -$0 | $0 | $2 | -$2 |
| Pre-Tax Income | -$9 | -$8 | -$6 | -$14 |
| Tax Expense | -$0 | $0 | $0 | -$1 |
| Net Income | -$7 | -$8 | -$6 | -$14 |
| % Margin | -14,514.6% | 3,575.9% | -338.4% | 5,038.2% |
| EPS | -0.054 | -0.099 | -0.071 | -0.28 |
| % Growth | 45.4% | -40.8% | 74.8% | – |
| EPS Diluted | -0.054 | -0.099 | -0.071 | -0.28 |
| Weighted Avg Shares Out | 128 | 83 | 83 | 51 |
| Weighted Avg Shares Out Dil | 128 | 83 | 83 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $1 | $1 | $2 |
| Depreciation & Amortization | $0 | $1 | $0 | $1 |
| EBITDA | -$6 | -$4 | -$7 | -$12 |
| % Margin | -12,211.8% | 1,766.2% | -424.9% | 4,065.4% |